Navigation Links
Sean P. Nolan Joins InterMune as Executive Vice President and Chief Business Officer
Date:2/14/2013

BRISBANE, Calif., Feb. 14, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Sean P. Nolan has joined InterMune as Executive Vice President and Chief Business Officer.

(Logo:  http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

In this newly created position, Mr. Nolan will lead the creation and establishment of InterMune's U.S. Commercial, Business Development and Global Marketing groups. He will also oversee InterMune's Canadian operations and the company's Manufacturing Operations and Supply Chain Management. Mr. Nolan will report to Dan Welch , Chairman, Chief Executive Officer and President of InterMune.

Mr. Welch said, "Sean will play a key role in InterMune's future as our Esbriet sales continue to grow globally, we move closer to the anticipated approval and launch of Esbriet in the United States and as we prepare to develop our business. I am confident that Sean will provide the broad and deep commercial and business experience, energy and drive that are essential during this exciting period of growth and change for our company."

Mr. Nolan began his career at Abbott Laboratories in 1991 and during a period of 13 years served in a variety of marketing and sales leadership positions. In 2004, he joined Ovation Pharmaceuticals, a privately held specialty pharmaceutical company focused on the development and commercialization of therapies to treat rare diseases. At Ovation, Sean developed and implemented the commercial strategies for the orphan drug pipeline and subsequently led the organization's effort that resulted in FDA approval of the company's lead compound. Ovation was acquired by the Danish pharmaceutical company, H. Lundbeck in 2009. After leading the company integration process, Mr. Nolan served as President of the newly created U.S. entity of Lundbeck. While at Lundbeck, Mr. Nolan served on the board of the Tuberous Sclerosis Alliance, and was co-chair of the Rare and Specialty Disease Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Mr. Nolan joins InterMune from Reata Pharmaceuticals, where he most recently served as Vice President and Chief Commercial Officer and built a commercial operation to support the company's lead product. 

About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved  for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AMRI Appoints Michael Nolan Vice President, Chief Financial Officer and Treasurer
2. Founder of Nestle-Acquired Company Joins Prismic Pharmaceuticals
3. Dr. Mickey Urdea Joins Pressure BioSciences Board of Directors
4. Natalie Douglas, CEO of Idis, Joins Global Genes
5. RARE Project Board of Directors
6. Breast Imaging Specialist Dr. Catherine D. Buhler Joins Radiologic Associates of Fredericksburg
7. Stephen Ondra, M.D., Joins Health Care Service Corporation As Enterprise Chief Medical Officer
8. Attorney Ellen Presby Joins The Nemeroff Law Firm In Dallas
9. Kevin Johnson Joins United Allergy Services Board Of Directors
10. Robert Funari Joins NxStage Board of Directors
11. B. Braun Joins National Health Organization Supporting Environmental Practices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... BRUSSELS , Dec. 2, 2016  UCB is pleased to ... presentation at the upcoming 70 th American Epilepsy Society ... Houston, TX , USA. 1-12 ... safety and efficacy profile of VIMPAT ® (lacosamide) CV ... also share findings on the current state of the union ...
(Date:12/2/2016)... NEW YORK , December 2, 2016 ... some of its past losses following Trump,s victory early ... growth potential, and fund managers are now predicting an ... look at four equities to see how they have ... CLDX ), Amicus Therapeutics Inc. (NASDAQ: ...
(Date:11/30/2016)... -- Research and Markets has announced the addition of ... report to their offering. ... Detachable coil embolization is a minimally ... detachable coil embolization treatment of cerebral aneurysms is less invasive and requires ... in the wall of an artery in the brain. This area bulges ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... More than 100 ... are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. This ... area students and operating support to UNCF-member institutions, including Miles College, Oakwood University, ...
(Date:12/2/2016)... ... 02, 2016 , ... Center for Autism and Related Disorders (CARD) Portland today ... spectrum disorder (ASD) and other developmental disabilities. The group, which is being launched with ... caregivers the opportunity to share stories and advice, seek help, and continue their education ...
(Date:12/2/2016)... ... ... With the number of pain management programs available for people suffering with constant ... works for them. When an inventor from Suisun City, Calif., was unsuccessful in finding ... it with others. , He developed a prototype for PRO GO MASSAGE to relieve ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than half of ... 84 percent of parents report speaking with their child about sex related topics, less ... diseases. , Mediaplanet is proud to announce the launch of its second edition of ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd ... Beach Resort and Spa in Honolulu, offering local frontline clinicians the opportunity to ... , The demand for supplemental training related to pain management has surged ...
Breaking Medicine News(10 mins):